Answers are grounded in this paper and cite their sources.
• Despite the well-established efficacy of third-generation EGFR-TKI in patients with mNSCLC, external validity of the outcome is generally unknown. • Our multisite observational research demonstrates the effectiveness of osimertinib for mNSCLC well aligns with clinical trial data and is superior to the outcomes of the first or second-generation TKIs. • The clinical outcome data account for potential savings in healthcare resource utilization, which is primarily attributable to the less frequent ancillary visits following osimertinib compared to the first or second generation EGFR-TKI. Osimertinib is a third-generation EGFR-TKI and preferred first-line (1L) treatment for EGFR positive ( EGFR+ ) metastatic non-small cell lung cancer (mNSCLC). This study compared real-world clinical outcomes of 1L osimertinib versus 1st or 2nd generation EGFR-TKIs (1/2G-TKIs) in patients with EGFR+ mNSCLC. Nine academic cancer centers in the US participated in the retrospective cohort study. Patients aged ≥18 years with EGFR+ mNSCLC and treated with 1L EGFR-TKI were included. Clinical outcomes included real-world progression-free survival (rwPFS), duration of treatment (DOT), time to next treatment (TTNT), central nervous system incidence-free survival (CNS-IFS), and overall survival (OS). Multivariable regression models were used to control for differences in patient characteristics ( p < 0.1) between the osimertinib and 1/2G-TKI cohorts. The study included 181 osimertinib patients and 171 1/2G-TKI patients. Osimertinib had a longer rwPFS compared to 1/2G-TKIs (median PFS, 95 % confidence interval [CI]: 16.2 months (13.2–19.7) vs. 10.8 months (9.5–12.7); hazard Ratio [HR], 95 % CI: 0.60 (0.44–0.82). DOT and TTNT were significantly longer in patients treated with osimertinib versus 1/2G-TKI (HR, 95 % CI: 0.51 (0.38–0.68) for DOT; 0.54 (0.39–0.74) for TTNT). The respective HR point estimate for CNF-IFS and OS of 0.62 and 0.83 preferred osimertinib. However, small patient counts and number of events posed challenges in drawing conclusion regarding the significance of the delayed CNS-IFS or OS. Patients treated with osimertinib had a prolonged time to progression and longer time maintain the treatment compared to 1/2G-TKI. This real-world evidence is aligned with clinical trial results.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: